Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
